A tighter archive for life-science signals.
Search once, then narrow by source or topic.
White House postpones planned TrumpRx launch event
White House postpones planned TrumpRx launch event
Sanofi vows to stay committed to vaccines as portfolio takes a hit
Sanofi vows to stay committed to vaccines as portfolio takes a hit
The disrupted fate of pharmacy startups
The disrupted fate of pharmacy startups
Sanofi's pipeline cuts; Breakthru Medicine raises $60M
Sanofi's pipeline cuts; Breakthru Medicine raises $60M
Summit gets November PDUFA date for its PD-1xVEGF bispecific
Summit gets November PDUFA date for its PD-1xVEGF bispecific
Trump looks to raise South Korea levies; Siegfried expands
Trump looks to raise South Korea levies; Siegfried expands
Agomab anticipates $182M IPO as it builds fibrosis pipeline
Agomab anticipates $182M IPO as it builds fibrosis pipeline
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff
Sanofi says its €15B dealmaking budget, R&D spend should help ease looming Dupixent patent cliff
Flagship's Repertoire gets another autoimmune partner in Lilly
Flagship's Repertoire gets another autoimmune partner in Lilly
Tenpoint gets FDA nod for presbyopia eye drop and $235M
Tenpoint gets FDA nod for presbyopia eye drop and $235M
ChenMed CEO warns against GLP-1s for seniors
ChenMed CEO warns against GLP-1s for seniors
Round three of IRA negotiations is expected to be ‘manageable’ for pharma
Round three of IRA negotiations is expected to be ‘manageable’ for pharma
Oral Rogaine maker Veradermics looks to raise $181M from IPO
Oral Rogaine maker Veradermics looks to raise $181M from IPO
FDA asks court to pause Louisiana's abortion pill fight
FDA asks court to pause Louisiana's abortion pill fight
Lonza still intends to sell its capsules and health ingredients business
Lonza still intends to sell its capsules and health ingredients business
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
Lonza still intends to sell its capsules and health ingredients business - Endpoints News
Teva CEO says it has successfully transitioned into a biopharma company
Teva CEO says it has successfully transitioned into a biopharma company
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page